# Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone

> **NCT04710641** · PHASE2 · COMPLETED · sponsor: **Mina Alpha Limited** · enrollment: 8 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Hepatitis B
- Hepatitis C

## Interventions

- **DRUG:** MTL-CEBPA
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT04710641
- **Lead sponsor:** Mina Alpha Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2025-01-25
- **Final completion:** 2025-01-25
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04710641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04710641, "Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04710641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*